drugset
drugset / Trial / NCT01682473

A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies

NCT01682473 ↗

Phase 1 Completed 20 enrolled Zenyaku Kogyo Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the safety (adverse events and dose-limiting toxicity) of daily oral doses of ZSTK474 in patients with advanced solid malignancies.

Timeline

Start
2012-09-20
Primary completion
2015-04-02
Completion
2015-04-20

Drugs

EvaluationDrugModalityDoseRoute
Subject ZSTK474 Small molecule — Oral

Indications

neoplasm